COMPETITION RESPONSE OF PSMA-I&T RADIOLABELED WITH LUTETIUM-177 TO LNCAP, PC-3 AND RWPE-1 CELLS

Introduction/Justification: 177Lu-PSMA-I&T stands out as a promisor radiopharmaceutical for therapy of prostate cancer based on the specific bind of Glu-urea-Lys pharmacophoric group prostate-specific membrane antigen (PSMA), anchored in the epithelial prostate cell membrane, overexpressed in pr...

Full description

Bibliographic Details
Published in:Hematology, Transfusion and Cell Therapy
Main Authors: Luiza M Balieiro, Luana Pereira da Silva, Luiz Felipe Teixeira da Silva, Laura Fernanda Garcia, Margareth Mie Nakamura Matsuda, Maria Helena Bellini Marumo, Elaine Bortoleti de Araújo
Format: Article
Language:English
Published: Elsevier 2025-05-01
Subjects:
Binding
Lutetium-177
PSMA-I&T
Radiopharmaceutical;
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137925000306

Internet

http://www.sciencedirect.com/science/article/pii/S2531137925000306

Similar Items